Vericel Corp
Research Vericel Corp (VCEL) on Bullrun: valuation model: 37.6% overvalued, market cap USD 2.30B, P/E 110.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVCEL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal37.6% overvalued
- Market capUSD 2.30B
- P/E110.2
- Financial periodFY2025
- RevenueUSD 276.26M
- Revenue growth16.5%
- Net incomeUSD 16.52M
- Free cash flowUSD 24.75M
- Gross margin74.4%
Valuation Snapshot
Bullrun's latest valuation model marks Vericel Corp as 37.6% overvalued; latest market cap is USD 2.30B; P/E is 110.2.
About Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee;
Frequently asked questions
Is Vericel Corp overvalued or undervalued?
Bullrun's valuation model currently marks Vericel Corp as 37.6% overvalued.
What is Vericel Corp's market cap?
Vericel Corp's market capitalization is USD 2.30B.
What is Vericel Corp's P/E ratio?
Vericel Corp's price-to-earnings (P/E) ratio is 110.2.
What does Vericel Corp do?
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.